Abstract
Through clinical practice, lenvatinib-based combination treatments are commonly used in patients with unresectable hepatocellular carcinoma (uHCC), but their curative effect warrants further investigation. This study compares the efficacy and safety of lenvatinib plus PD-1 inhibitor and TACE (LPT) vs. lenvatinib plus PD-1 inhibitor (LP) in uHCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
